Seoulin Bioscience Current Valuation vs. Cash And Equivalents
| 038070 Stock | KRW 7,500 40.00 0.53% |
For Seoulin Bioscience profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Seoulin Bioscience to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Seoulin Bioscience CoLtd utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Seoulin Bioscience's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Seoulin Bioscience CoLtd over time as well as its relative position and ranking within its peers.
Seoulin |
Seoulin Bioscience CoLtd Cash And Equivalents vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Seoulin Bioscience's current stock value. Our valuation model uses many indicators to compare Seoulin Bioscience value to that of its competitors to determine the firm's financial worth. Seoulin Bioscience CoLtd is the top company in current valuation category among its peers. It also is number one stock in cash and equivalents category among its peers creating about 0.09 of Cash And Equivalents per Current Valuation. The ratio of Current Valuation to Cash And Equivalents for Seoulin Bioscience CoLtd is roughly 11.05 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Seoulin Bioscience by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Seoulin Bioscience's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Seoulin Current Valuation vs. Competition
Seoulin Bioscience CoLtd is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 1.32 Trillion. Seoulin Bioscience retains roughly 165.44 Billion in current valuation claiming about 12% of equities under Health Care industry.
Seoulin Cash And Equivalents vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Seoulin Bioscience |
| = | 165.44 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Seoulin Bioscience |
| = | 14.97 B |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Seoulin Cash And Equivalents Comparison
Seoulin Bioscience is currently under evaluation in cash and equivalents category among its peers.
Seoulin Bioscience Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Seoulin Bioscience, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Seoulin Bioscience will eventually generate negative long term returns. The profitability progress is the general direction of Seoulin Bioscience's change in net profit over the period of time. It can combine multiple indicators of Seoulin Bioscience, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
,Ltd., a bio healthcare company, provides solutions in life sciences and healthcare primarily in South Korea. The company was founded in 1984 and is headquartered in Seongnam, South Korea. SeouLin is traded on Korean Securities Dealers Automated Quotations in South Korea.
Seoulin Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Seoulin Bioscience. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Seoulin Bioscience position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Seoulin Bioscience's important profitability drivers and their relationship over time.
Use Seoulin Bioscience in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Seoulin Bioscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Seoulin Bioscience will appreciate offsetting losses from the drop in the long position's value.Seoulin Bioscience Pair Trading
Seoulin Bioscience CoLtd Pair Trading Analysis
The ability to find closely correlated positions to Seoulin Bioscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Seoulin Bioscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Seoulin Bioscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Seoulin Bioscience CoLtd to buy it.
The correlation of Seoulin Bioscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Seoulin Bioscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Seoulin Bioscience CoLtd moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Seoulin Bioscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Seoulin Bioscience position
In addition to having Seoulin Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Marketing Thematic Idea Now
Marketing
Companies providing marketing and public relation (PR) services as well as news and media distribution. The Marketing theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marketing Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Seoulin Stock
To fully project Seoulin Bioscience's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Seoulin Bioscience CoLtd at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Seoulin Bioscience's income statement, its balance sheet, and the statement of cash flows.